Navigation Links
ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Date:5/7/2009

study drugs, had no major violations of the inclusion/exclusion criteria and had complete pharmacokinetic data were included in the analysis.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a formulation of which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose proprietary product candidates are designed to improve the safety and commercial potential of existing cancer treatments. In December 2008, the Company announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets. In January and March 2009, the Company announced headcount reductions and cost containment measures to provide additional time to consummate a strategic transaction or otherwise obtain financing. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they ma
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
2. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
3. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
4. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
5. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
8. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
9. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
10. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... NASHVILLE, Tenn. , April 30, 2015  Cumberland ... it will release first quarter 2015 financial results after ... conference call and live Internet webcast will be held ... Time to discuss the results. To participate ... or 253-237-1032 (for international callers).  A rebroadcast of the ...
(Date:4/30/2015)... 2015  Nektar Therapeutics (Nasdaq: NKTR ) today ... March 31, 2015. Cash and investments ... million as compared to $262.8 million at December 31, ... March 31, 2015 includes a $100.0 million milestone payment ... commercial sale of Movantik™(naloxegol) in the U.S. ...
(Date:4/30/2015)... plc (NYSE: PRGO ; TASE) today announced that Perrigo Chairman, ... the 2015 Deutsche Bank 40 th Annual Healthcare Conference at ... in Boston , MA.  The ... C. Papa will present at the Bank of America Merrill ... 2015 at the Encore at Wynn Las Vegas Hotel in ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 2Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 3Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 4Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 5Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 6Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 7Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 8Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 9Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 10Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 11Nektar Therapeutics Reports Financial Results for the First Quarter of 2015 12Perrigo Company To Present At Upcoming Healthcare Conferences 2Perrigo Company To Present At Upcoming Healthcare Conferences 3
... Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that ... New Drugs ("OND") in Maryland and presented its arguments supporting ... Drug Application ("NDA") 22-481 support the conclusion that pixantrone is ... consideration of our appeal.  While we understand disputes of this ...
... SQNM ), today announced the awards of non-qualified ... common stock for six new employees under the company,s New ... Of these shares, 14,450 have an exercise price ... Sequenom,s common stock on February 28, and 60,000 have a ...
Cached Medicine Technology:FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone 2FDA's Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone 3Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
(Date:5/1/2015)... Frisco, Texas (PRWEB) May 02, 2015 ... Frisco, Texas, is proud to announce the addition of ... Jen Widerstrom is a life long athlete, growing up ... fitness passion after college by becoming a personal trainer ... since been the face of several TV shows highlighting ...
(Date:5/1/2015)... Va. (PRWEB) May 01, 2015 The ... nation’s leading nonprofit authority on the use of health ... as a key contributing resource to the United States ... use of electronically readable cards in Medicare. The report, ... and Providers ” was released to the public on ...
(Date:5/1/2015)... Linda, CA (PRWEB) May 01, 2015 ... our genetic makeup and the interplay of genes with ... up with developments can be daunting. , LabRoots, the ... and clinical diagnostics professionals, will soon host its annual ... , At BioConference Live Genetics and Genomics 2015 ...
(Date:5/1/2015)... May 01, 2015 The frozen yogurt ... the Hickory Crawdads (NC) and the Myrtle Beach Pellicans ... in-stadium concession locations and offer fans discounts at local ... the Hickory Community,” said Luke Shook, co-owner of the ... opportunity and we look forward to enjoying the games ...
Breaking Medicine News(10 mins):Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:IDLife LLC Announces New Partnership with Fitness Celebrity, Jen Widerstrom 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3Health News:sweetFrog Announces Minor League Baseball Partnerships 2
... cancer treatment, chemobrain a range of symptoms including ... subtle cognitive changes following chemotherapy seriously diminishes women,s ... they have to adopt a range of coping strategies ... Breast cancer survivors tell their story in a ...
... , SAN DIEGO, Sept. 17 ... that the company,s first laboratory developed test, the SensiGene(TM) Cystic ... is available exclusively through the Sequenom Center for Molecular Medicine, ... laboratory and a wholly-owned subsidiary of Sequenom, Inc. , ...
... Office of Minority Health Urges "Know Your Risk and Help ... 17 Speaking at the Venous Disease Coalition (VDC) Annual Meeting ... the Department of Health and Human Services followed up on last ... African American population which is at significantly increased risk of Deep ...
... , DALLAS, Sept. 17 The Texas ... released its annual report on the prevalence, cost and quality ... includes information for key local markets across the state including ... Also included are state and national benchmarks that can help ...
... set by CDC need to be lowered, experts say , ... levels well below those considered safe are still at risk ... , Currently, the maximum safe blood level of lead is ... the U.S. Centers for Disease Control and Prevention in 1991. ...
... ... communications company. , ... Knoxville, TN (PRWeb) Sept. 17, 2009 -- Alan Weinstein was recently named chairman of ... innovative ways to leverage PerfectServe,s physician-contact network serving physician practices and hospitals nationwide. , ...
Cached Medicine News:Health News:Chemobrain -- the flip side of surviving cancer 2Health News:SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 2Health News:SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 3Health News:SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 4Health News:SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 5Health News:SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test 6Health News:African Americans at Significantly Higher Risk of DVT or Blood Clots 2Health News:African Americans at Significantly Higher Risk of DVT or Blood Clots 3Health News:African Americans at Significantly Higher Risk of DVT or Blood Clots 4Health News:TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 2Health News:TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 3Health News:TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 4Health News:Even Small Amounts of Lead Harmful to Kids 2Health News:Even Small Amounts of Lead Harmful to Kids 3Health News:Alan Weinstein Named Chairman of PerfectServe Advisory Board 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: